

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
18467

In Re Application Of: Lloyd S. Gray, et al.



Application No.	Filing Date	Inventor	Customer No.	Group Art Unit	Confirmation No.
10/589,216	August 11, 2006	Unassigned	23389	Unassigned	Unassigned

Title:

**INHIBITING CAV3 ISOFORMS AND THE δ 25B SPLICE VARIANTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER**

Address to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 18467	
In Re Application of: Lloyd S. Gray, et al.					
Application No. 10/589,216	Filing Date August 11, 2006	Customer No. Unassigned	Group Art Unit Unassigned	Confirmation No. Unassigned	
Title: INHIBITING CAV3 ISOFORMS AND THE 25B SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER					
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))					
<input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>19-1013/SSMP</u> as described below.					
<input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
Certificate of Transmission by Facsimile* I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa _____ (Date) _____ Signature _____ Typed or Printed Name of Person Signing Certificate			Certificate of Mailing by First Class Mail I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on January 9, 2007 _____ (Date) _____ Signature of Person Mailing Correspondence Peter I. Bernstein _____ Typed or Printed Name of Person Mailing Certificate		
*This certificate may only be used if paying by deposit account. _____ Signature Peter I. Bernstein Registration No. 43,497 Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza, Suite 300 Garden City, New York 11530 516-742-4343					
Dated: January 9, 2007					
CC:					

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Lloyd S. Gray, et al. **Examiner:** Unassigned
Serial No: 10/589,216 **Art Unit:** Unassigned
Filed: August 11, 2006 **Docket:** 18467
For: INHIBITING CAV3 ISOFORMS AND **Dated:** January 9, 2007
THE δ 25B SPLICE VARIANTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 6,191,156 B1, dated February 20, 2001 to Kifor et al.;
2. United States Patent No. 6,255,457 B1, dated July 3, 2001 to Schnitzer; and
3. Song K.S. et al., "Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells", *The Journal of Biological Chemistry*, 271(25):15160-15165 (1996).

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


Dated: January 9, 2007

Peter I. Bernstein

The references were cited in an International Search Report dated December 18, 2006. Applicants are submitting a copy of Reference No. 3. In accordance with 37 C.F.R. § 1.98 (a)(2)(i), Applicants are not required to submit a copy of the above-cited U.S. Patent references. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is also being submitted in accordance with the schedule set out in 37 C.F.R. § 1.704(d), a statement is attached.

Respectfully submitted,



Peter I. Bernstein
Registration No.: 43,497


Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg

Receipt date: 01/16/2007

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

18467

10589218 - GAU: 4111
10/589,216

Applicant(s)

Lloyd S. Gray, et al.

Filing Date

August 11, 2006

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,191,156 B1	2/20/01	Kifor et al.			
		6,255,457 B1	7/3/01	Schnitzer			

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

		Song K.S. et al., "Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells", The Journal of Biological Chemistry, 271(25):15160-15165 (1996)

EXAMINER

/Yan Xiao/

DATE CONSIDERED

11/29/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Lloyd S. Gray, et al. **Examiner:** Unassigned
Serial No: 10/589,216 **Art Unit:** Unassigned
Filed: August 11, 2006 **Docket:** 18467
For: INHIBITING CAV3 ISOFORMS AND **Dated:** January 9, 2007
THE δ 25B SPLICE VARIANTS FOR THE
DIAGNOSIS AND TREATMENT OF CANCER

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

STATEMENT PURSUANT TO 37 C.F.R. § 1.704(d)


Sir:

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 9, 2007


Peter I. Bernstein

Therefore, this Information Disclosure Statement cannot be considered a failure to engage in reasonable efforts to conclude prosecution of the application under paragraphs (c)(6), (c) (8), (c) (9), or (c) (10) of 37 C.F.R. § 1.704.

Respectfully submitted,



Peter I. Bernstein

Registration No.: 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

PIB:dg